Melanoma Clinical Trials in Salt Lake City

Showing 201-220 of 244 trials

Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma

NCT02200562

Phase I/II study of ipilimumab concurrent ipilimumab and dabrafenib as first line treatment in Stage III or IV melanoma. Assessing safety of Ipilimumab and dabrafenib in combination. Also, assessing disease control rates.

Stage III or IV Melanoma

University of Utah6 participantsStarted Dec 2014

Salt Lake City, Utah, United States

COMPLETEDPhase 3< 1 mile

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

NCT00769704

The objective of this study is to evaluate the efficacy and safety of treatment with talimogene laherparepvec compared to subcutaneously administered GM-CSF in patients with unresectable Stage IIIb, IIIc and Stage IV melanoma. The efficacy endpoints of the study aim to demonstrate overall clinical benefit for patients treated with talimogene laherparepvec as compared to GM-CSF.

Melanoma

BioVex Limited437 participantsStarted Apr 2009

Tucson, Arizona, United States • Little Rock, Arkansas, United States • La Jolla, California, United States +80 more locations

Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Melanoma Trials in Other Cities

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

CCI-779 in Treating Patients With Metastatic Melanoma

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Phase II, 2nd Line Melanoma - RAND Monotherapy

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Other Conditions in Salt Lake City